Home/Pipeline/New TCM Formulations

New TCM Formulations

Not Specified

Research / Pre-clinicalDevelopment

Key Facts

Indication

Not Specified

Phase

Research / Pre-clinical

Status

Development

Company

China SXT Pharmaceuticals

About China SXT Pharmaceuticals

China SXT Pharmaceuticals (NASDAQ: SXTC) is a China-based specialty pharmaceutical company with a dual-mission to modernize Traditional Chinese Medicine (TCM) and produce generic drugs. The company has established an integrated operational model, managing R&D, manufacturing, and commercialization in-house, primarily targeting high-prevalence conditions in its domestic market. Its strategy hinges on capitalizing on government support for TCM integration into the healthcare system and the ongoing demand for affordable generic pharmaceuticals, though it faces significant execution and competitive risks.

View full company profile

Therapeutic Areas

Cardiovascular Central Nervous System Digestive Metabolic

Other Not Specified Drugs

Drug	Company	Phase	Status
Long-acting Leronlimab	CytoDyn	Preclinical	Phase in progress
Collaborative Program with Ferring	PharmaBiome	Research	Active
Lighthouse Pilot Product	Cipherome	Pilot	Launched 2020
Nitric Oxide + Collagen Delivery	Jellagen	Research	Active
Undisclosed	Authera	Pre-clinical	Active
mRNA Therapeutics Platform Application	Lupagen	Research	Active
PHYRAGO	Handa Pharmaceuticals	Approved	Active
TASCENSO ODT	Handa Pharmaceuticals	Approved	Active
Axulin	Housey Pharmaceutical Research Laboratories	Commercial	Active
PBI-04711	Phoenix Biotechnology	Pre-clinical	Active
Immunology Program	Ignite Biomedical	Discovery	Active
Sunobinop	Imbrium Therapeutics	Not specified	Active